Minimal Residual Disease Testing Market

Home Healthcare And Pharmaceutical Minimal Residual Disease Testing Market

Minimal Residual Disease Testing Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Test Type (DNA-based Test, RNA-based Test, Immunological Test); By Technology (NGS, PCR, Flow Cytometry, Fluorescence In-situ Hybridization); By Application (Hematological Malignancies, Solid Tumors); By End Use (Hospitals, Specialty Clinics, Diagnostic Laboratories, Research & Academic Institutes); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published Date: May 2023
Report ID: BWC23357
Available Format: PDF
Page: 400

Report Overview

Growing prevalence of cancer worldwide leading to an increased demand for accurate and reliable diagnostic tests, increasing adoption of precision medicine approaches, and growing trend towards early cancer diagnosis and detection are projected to propel the expansion of global minimal residual disease testing market during the forecast period between 2023 and 2029.

Global Minimal Residual Disease Testing Market - Industry Trends & Forecast Report, 2029

Global minimal residual disease testing market size was estimated at USD 1.54 billion in 2022. During the forecast period between 2023 and 2029, the size of global minimal residual disease testing market is projected to grow at CAGR of 14.6% reaching a value of USD 3.96 billion by 2029. Major growth drivers for global minimal residual disease testing market include rising cancer rates, growing recognition among consumers of the importance of therapy, as well as increased investments in research, and high disposable income in developing nations. Another primary driver of market growth during the forecast period is the escalating prevalence of cancer. According to the World Health Organization, cancer is currently the second most common cause of death worldwide. In 2020, there were 19.3 million reported cases of cancer and 9.96 million deaths related to the disease. The International Agency for Research on Cancer predicts that the number of cancer cases will rise to 21.9 million by 2025 and 24.6 million by 2030. As a result, governments are expected to establish new cancer screening programs to address this surge in cases. Also, the market is expected to experience growth due to increased investments in MRD (minimal residual disease) testing programs. MRD diagnostic and monitoring research is expanding, which is creating demand for these services.

Global Minimal Residual Disease Testing Market

Global Minimal Residual Disease Testing Market – Overview

Global minimal residual disease (MRD) testing market refers to the market for diagnostic tests used to detect the presence of cancer cells in patients who have undergone treatment. MRD testing is a highly sensitive and specific technique that is capable of detecting small amounts of cancer cells that may remain in a patient's body after treatment. The MRD testing market includes products and services such as assays, flow cytometers, and other testing equipment, as well as related services such as sample preparation and analysis. The market caters to healthcare providers, research organizations, and pharmaceutical companies who use MRD testing for disease monitoring, treatment selection, and clinical trial endpoints.

Global Minimal Residual Disease Testing Market

Growth Drivers

Growing Focus on Early Cancer Diagnosis and Detection

The growing trend towards early cancer diagnosis and detection refers to the increasing emphasis on detecting cancer in its preliminary stages, before symptoms appear or the disease has advanced. Early diagnosis can lead to better treatment outcomes and increased chances of survival. This trend is driven by several factors, including public awareness campaigns, advances in screening technologies, and a greater emphasis on preventive healthcare. As a result, there is a greater demand for diagnostic tests that can detect cancer in its initial stages, including MRD testing.

Restraints

Challenges in Applying MRD Tests due to Stringent and Intricate Regulations

The application of MRD tests is governed by stringent and intricate regulations, similar to other diagnostic and treatment procedures. Various concerns regarding the effectiveness and appropriateness of these tests arise, depending on the type of test being used. For instance, while multiparameter flow cytometry tests can be complicated to interpret, they may not identify certain cytogenetic traits. Consequently, the combination of rigorous rules and limitations of MRD tests impedes the development and advancement of the minimal residual disease testing industry.

Impact of COVID-19 on Global Minimal Residual Disease Testing Market

COVID-19 adversely affected the global minimal residual disease (MRD) testing market. With the focus on the virus and the strain on healthcare systems, the demand for MRD testing was affected. The restrictions imposed due to the pandemic, such as social distancing and lockdown measures, also resulted in delays or cancellations of elective procedures, including MRD testing. Also, the disruption in the supply chain and manufacturing processes led to a shortage of necessary components and instruments required for testing. The uncertain economic conditions and reduced funding for research and development may further impede the growth of the MRD testing market in the near future.

Global Minimal Residual Disease Testing Market

Segmental Coverage

Global Minimal Residual Disease Testing Market – By Test Type

Based on test type, the global minimal residual disease testing market is divided into DNA-based Test, RNA-based Test, and Immunological Test. The DNA-based tests segment held the highest share of the MRD testing market due to their high sensitivity and specificity in detecting cancer cells. However, the RNA-based tests segment was expected to grow at the fastest CAGR during the forecast period due to advancements in technologies such as next-generation sequencing (NGS) and digital PCR.

Minimal Residual Disease Testing Market

Global Minimal Residual Disease Testing Market – By Technology

Based on technology, the global minimal residual disease testing market is divided into NGS, PCR, Flow Cytometry, and Fluorescence In-situ Hybridization segments. The flow cytometry segment held the highest share in the global minimal residual disease testing market in 2022, due to its high sensitivity and broad applicability. This technique involves evaluating individual cells to determine the presence of specific protein markers on their surface. A recent bone marrow sample is required for reliable results, and special antibodies are applied to the sample to identify cells with particular proteins. Depending on the flow cytometry configuration, this approach can detect a single cancer cell among 10,000 to 100,000 healthy bone marrow cells, and results can be obtained in less than a day. During the forecast period, the polymerase chain reaction (PCR) technology segment is expected to experience significant growth. The PCR method can detect cancer cells based on unique genetic anomalies, such as chromosomal alterations or mutations. PCR amplifies small DNA or RNA fragments to enhance their detectability, allowing it to identify genetic anomalies even when very few cancer cells are present. Blood cells or bone marrow samples are used for the test, and PCR can detect one cancer cell among 100,000 normal cells. However, the time required for test results to be available is typically between 5 and 14 days.

Global Minimal Residual Disease Testing Market – By Application

Based on application, the global minimal residual disease testing market is bifurcated into Hematological Malignancies and Solid Tumors segments. In 2022, the hematological malignancy cancer segment held a higher market share for MRD testing, as the use of MRD testing as a diagnostic and monitoring tool increased in these cancers. Hematological malignancies are cancers that start in blood-forming tissues or immune system cells, including leukemia, lymphoma, and multiple myeloma. The ClonoSEQ assay, which uses NGS technology, is FDA-approved for detecting and monitoring MRD in bone marrow samples from patients with multiple myeloma. The prevalence of hematological malignancies has also been on the rise. During the forecast period, the solid tumors segment is expected to witness significant growth, driven by ongoing research on the assessment of patients with solid tumors. Currently, there are no approved recommendations for using MRD testing in nonhematologic malignancies. However, the use of circulating tumor-derived DNA (ctDNA) as a prognostic biomarker for MRD after therapy for solid tumors is rapidly being incorporated into clinical trial design and translational research investigations and poised for standard clinical use. Nevertheless, the poor sensitivity of current detection methods limits their usefulness for MRD detection across a range of clinical applications, even as ctDNA detection technologies continue to evolve rapidly.

Minimal Residual Disease Testing Market Share

Global Minimal Residual Disease Testing Market – By End Use

Based on end use, the global minimal residual disease testing market is divided into Hospitals, Specialty Clinics, Diagnostic Laboratories, and Research & Academic Institutes segments. In 2022, the hospitals segment held the highest market share in the global MRD testing market. Hospitals offer specialized expertise to help patients choose the most appropriate MRD tests. The market growth is driven by several factors, including the increasing prevalence of the target condition, the availability of multiple testing options, and the launch of new tests for better and more effective patient screening. Hospital facilities also provide better decision-making capabilities, allowing doctors and healthcare professionals to analyze patient data and provide optimal treatment options. During the forecast period, the academic and research institutes segment is expected to exhibit significant growth. This growth is associated with increasing research activities aimed at identifying candidates and establishing patient diagnoses for research participation. MRD testing for multiple myeloma is increasingly being used in clinical trials to evaluate disease response and predict the length of response. Preliminary evidence suggests that MRD positivity following treatment is associated with a higher risk of relapse, while MRD negativity results in improved progression-free survival (PFS). Furthermore, studies are being conducted to examine the relevance of sequential MRD monitoring in patients undergoing treatment.

Minimal Residual Disease Testing Market Size

Global Minimal Residual Disease Testing Market – By Region

The in-depth research report on the global minimal residual disease testing market covers country-specific markets across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa (MEA). North America held the highest share in the global minimal residual disease testing market due to the increasing incidence of cancer, the adoption of next-generation and polymerase chain reaction techniques, the adoption of innovative technology, and the availability of research infrastructure for proteomics, genomics, and oncology. The increasing prevalence of hematological cancers in the United States has resulted in a higher risk of residual cancerous cells, which is expected to drive demand for minimal residual disease market. The American Cancer Society has reported that 34,470 new cases of multiple myeloma and 6,660 new cases of acute lymphocytic leukemia are expected in the United States in 2022. Additionally, the Leukemia and Lymphoma Society has projected that 90,390 new lymphoma cases will be diagnosed in the United States in 2021. Furthermore, the market growth is also attributed to the increasing focus of companies on developing treatments and tests for detecting minimal residual disease.

Competitive Landscape

Major players operating in the global minimal residual disease testing market include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Recent Developments

In June 2021 - Sysmex Corporation launched a new MRD testing solution, Sysmex Inostics OncoBEAM Plus Digital PCR Kit. The solution is designed to detect and monitor low levels of MRD in patients with solid tumors.

Scope of the Report

Attributes	Details
Years Considered	Historical Data – 2019–2022
	Base Year – 2022
	Estimated Year – 2023
	Forecast Period – 2023–2029
Facts Covered	Revenue in USD Billion
Market Coverage	North America, Europe, Asia Pacific (APAC), Latin America, Middle East and Africa (MEA)
Product/ Service Segmentation	Test Type, Technology, Application, End Use, Region
Key Players	Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, Thermo Fisher Scientific, Inc.

By Test Type

DNA-based Test
RNA-based Test
Immunological Test

By Technology

NGS
PCR
Flow Cytometry
Fluorescence In-Situ Hybridization

By Application

Hematological Malignancies
Solid Tumors

By End Use

Hospitals
Specialty Clinics
Diagnostic Laboratories
Research & Academic Institutes

By Region

North America
Europe
Asia Pacific (APAC)
Latin America
Middle East and Africa (MEA)

Research Framework
1. Research Objective
2. Product Overview
3. Market Segmentation
Executive Summary
Global Minimal Residual Disease Testing Market Insights
1. Industry Value Chain Analysis
2. DROC Analysis
  1. Growth Drivers
    1. Growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests
    2. Increasing adoption of precision medicine approaches
    3. Growing trend towards early cancer diagnosis and detection
  2. Restraints
    1. Limited availability of skilled healthcare professionals to perform and interpret MRD tests
    2. Concerns over the accuracy and reliability of MRD tests
  3. Opportunities
    1. Increasing adoption of advanced technologies, such as next-generation sequencing
    2. Growing trend towards personalized cancer care, which requires accurate and reliable measurement
  4. Challenges
    1. Need for continuous investment in research and development to stay competitive
3. Technology Advancements/Recent Developments
4. Regulatory Framework
5. Porter’s Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of New Entrants
  4. Threat of Substitutes
  5. Intensity of Rivalry
Global Minimal Residual Disease Testing Market Overview
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share and Forecast
  1. By Test Type
    1. DNA-Based Test
    2. RNA-Based Test
    3. Immunological Test
    4. Others
  2. By Technology
    1. NGS, PCR
    2. Flow Cytometry
    3. Fluorescence In-Situ Hybridization
    4. Others
  3. By Application
    1. Hematological Malignancies
    2. Solid Tumors
    3. Others
  4. By End Use
    1. Hospitals
    2. Specialty Clinics
    3. Diagnostic Laboratories
    4. Research and Academic Institutes
    5. Others
  5. By Region
    1. North America
    2. Europe
    3. Asia Pacific (APAC)
    4. Latin America (LATAM)
    5. Middle East and Africa (MEA)
North America Minimal Residual Disease Testing Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Test Type
  2. By Technology
  3. By Application
  4. By End Use
  5. By Country
    1. United States
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    2. Canada
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
Europe Minimal Residual Disease Testing Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Test Type
  2. By Technology
  3. By Application
  4. By End Use
  5. By Country
    1. Germany
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    2. United Kingdom
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    3. Italy
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    4. France
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    5. Spain
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    6. Belgium
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    7. Russia
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    8. The Netherlands
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    9. Rest of Europe
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
Asia-Pacific Minimal Residual Disease Testing Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Test Type
  2. By Technology
  3. By Application
  4. By End Use
  5. By Country
    1. China
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    2. India
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    3. Japan
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    4. South Korea
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    5. Australia & New Zealand
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    6. Indonesia
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    7. Malaysia
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    8. Singapore
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    9. Vietnam
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    10. Rest of APAC
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
Latin America Minimal Residual Disease Testing Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Test Type
  2. By Technology
  3. By Application
  4. By End Use
  5. By Country
    1. Brazil
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    2. Mexico
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    3. Argentina
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    4. Peru
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    5. Rest of LATAM
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
Middle East & Africa Minimal Residual Disease Testing Market
1. Market Size & Forecast, 2019–2029
  1. By Value (USD Million)
2. Market Share & Forecast
  1. By Test Type
  2. By Technology
  3. By Application
  4. By End Use
  5. By Country
    1. Saudi Arabia
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    2. UAE
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    3. Qatar
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    4. Kuwait
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    5. South Africa
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    6. Nigeria
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    7. Algeria
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
    8. Rest of MEA
      1. By Test Type
      2. By Technology
      3. By Application
      4. By End Use
Competitive Landscape
1. List of Key Players and Their Offerings
2. Global Minimal Residual Disease Testing Market Share Analysis, 2022
3. Competitive Benchmarking, By Operating Parameters
4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
Impact of Covid-19 on Global Minimal Residual Disease Testing Market
Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
1. Abbott Laboratories
2. Adaptive Biotechnologies
3. Agilent Technologies
4. ARUP Laboratories
5. Bio-Rad Laboratories
6. F. Hoffmann-La Roche AG
7. Illumina, Inc.
8. Invivoscribe, Inc.
9. Janssen Diagnostics LLC
10. Luminex Corporation
11. Myriad Genetics, Inc.
12. Natera, Inc.
13. QIAGEN N.V.
14. Sysmex Corporation
15. Thermo Fisher Scientific, Inc.
16. Other Prominent Players
Key Strategic Recommendations
Research Methodology
1. Qualitative Research
  1. Primary & Secondary Research
2. Quantitative Research
3. Market Breakdown & Data Triangulation
  1. Secondary Research
  2. Primary Research
4. Breakdown of Primary Research Respondents, By Region
5. Assumptions & Limitations

*Financial information of case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

List of Figures

Figure 1 Global Minimal Residual Disease Testing Segmentation

Figure 2 Global Minimal Residual Disease Testing Market Value Chain Analysis

Figure 3 Company Market Share Analysis, 2021

Figure 4 Global Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 5 Global Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 6 Global Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 7 Global Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 8 Global Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 9 Global Minimal Residual Disease Testing Market Share, By Region, By Value, 2019–2029

Figure 10 North America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 11 North America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 12 North America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 13 North America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 14 North America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 15 North America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 16 United States Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 17 United States Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 18 United States Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 19 United States Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 20 United States Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 21 Canada Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 22 Canada Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 23 Canada Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 24 Canada Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 25 Canada Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 26 Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 27 Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 28 Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 29 Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 30 Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 31 Europe Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 32 Germany Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 33 Germany Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 34 Germany Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 35 Germany Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 36 Germany Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 37 UNITED KINGDOM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 38 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 39 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 40 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 41 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 42 Italy Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 43 Italy Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 44 Italy Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 45 Italy Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 46 Italy Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 47 France Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 48 France Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 49 France Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 50 France Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 51 France Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 52 Spain Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 53 Spain Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 54 Spain Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 55 Spain Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 56 Spain Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 57 Belgium Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 58 Belgium Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 59 Belgium Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 60 Belgium Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 61 Belgium Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 62 Russia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 63 Russia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 64 Russia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 65 Russia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 66 Russia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 67 The Netherlands Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 68 The Netherlands Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 69 The Netherlands Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 70 The Netherlands Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 71 The Netherlands Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 72 Rest of Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 73 Rest of Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 74 Rest of Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 75 Rest of Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 76 Rest of Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 77 Asia-Pacific Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 78 Asia-Pacific Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 79 Asia-Pacific Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 80 Asia-Pacific Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 81 Asia-Pacific Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 82 Asia-Pacific Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 83 China Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 84 China Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 85 China Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 86 China Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 87 China Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 88 India Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 89 India Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 90 India Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 91 India Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 92 India Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 93 Japan Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 94 Japan Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 95 Japan Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 96 Japan Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 97 Japan Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 98 South Korea Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 99 South Korea Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 100 South Korea Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 101 South Korea Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 102 South Korea Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 103 Australia & New Zealand Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 104 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 105 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 106 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 107 Australia & New Zealand Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 108 Indonesia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 109 Indonesia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 110 Indonesia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 111 Indonesia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 112 Indonesia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 113 Malaysia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 114 Malaysia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 115 Malaysia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 116 Malaysia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 117 Malaysia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 118 Singapore Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 119 Singapore Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 120 Singapore Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 121 Singapore Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 122 Singapore Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 123 Vietnam Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 124 Vietnam Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 125 Vietnam Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 126 Vietnam Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 127 Vietnam Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 128 Rest of APAC Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 129 Rest of APAC Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 130 Rest of APAC Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 131 Rest of APAC Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 132 Rest of APAC Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 133 Latin America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 134 Latin America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 135 Latin America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 136 Latin America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 137 Latin America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 138 Latin America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 139 Brazil Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 140 Brazil Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 141 Brazil Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 142 Brazil Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 143 Brazil Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 144 Mexico Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 145 Mexico Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 146 Mexico Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 147 Mexico Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 148 Mexico Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 149 Argentina Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 150 Argentina Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 151 Argentina Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 152 Argentina Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 153 Argentina Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 154 Peru Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 155 Peru Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 156 Peru Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 157 Peru Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 158 Peru Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 159 Rest of LATAM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 160 Rest of LATAM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 161 Rest of LATAM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 162 Rest of LATAM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 163 Rest of LATAM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 164 Middle East & Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 165 Middle East & Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 166 Middle East & Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 167 Middle East & Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 168 Middle East & Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 169 Middle East & Africa Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Figure 170 Saudi Arabia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 171 Saudi Arabia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 172 Saudi Arabia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 173 Saudi Arabia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 174 Saudi Arabia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 175 UAE Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 176 UAE Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 177 UAE Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 178 UAE Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 179 UAE Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 180 Qatar Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 181 Qatar Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 182 Qatar Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 183 Qatar Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 184 Qatar Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 185 Kuwait Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 186 Kuwait Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 187 Kuwait Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 188 Kuwait Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 189 Kuwait Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 190 South Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 191 South Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 192 South Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 193 South Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 194 South Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 195 Nigeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 196 Nigeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 197 Nigeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 198 Nigeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 199 Nigeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 200 Algeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 201 Algeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 202 Algeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 203 Algeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 204 Algeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Figure 205 Rest of MEA Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Figure 206 Rest of MEA Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Figure 207 Rest of MEA Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Figure 208 Rest of MEA Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Figure 209 Rest of MEA Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

List of Tables

Table 1 Global Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 2 Global Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 3 Global Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 4 Global Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 5 Global Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 6 Global Minimal Residual Disease Testing Market Share, By Region, By Value, 2019–2029

Table 7 North America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 8 North America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 9 North America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 10 North America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 11 North America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 12 North America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 13 United States Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 14 United States Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 15 United States Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 16 United States Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 17 United States Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 18 Canada Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 19 Canada Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 20 Canada Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 21 Canada Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 22 Canada Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 23 Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 24 Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 25 Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 26 Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 27 Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 28 Europe Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 29 Germany Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 30 Germany Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 31 Germany Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 32 Germany Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 33 Germany Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 34 UNITED KINGDOM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 35 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 36 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 37 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 38 UNITED KINGDOM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 39 Italy Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 40 Italy Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 41 Italy Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 42 Italy Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 43 Italy Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 44 France Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 45 France Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 46 France Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 47 France Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 48 France Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 49 Spain Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 50 Spain Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 51 Spain Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 52 Spain Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 53 Spain Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 54 Belgium Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 55 Belgium Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 56 Belgium Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 57 Belgium Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 58 Belgium Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 59 Russia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 60 Russia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 61 Russia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 62 Russia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 63 Russia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 64 The Netherlands Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 65 The Netherlands Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 66 The Netherlands Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 67 The Netherlands Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 68 The Netherlands Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 69 Rest of Europe Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 70 Rest of Europe Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 71 Rest of Europe Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 72 Rest of Europe Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 73 Rest of Europe Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 74 Asia-Pacific Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 75 Asia-Pacific Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 76 Asia-Pacific Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 77 Asia-Pacific Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 78 Asia-Pacific Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 79 Asia-Pacific Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 80 China Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 81 China Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 82 China Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 83 China Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 84 China Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 85 India Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 86 India Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 87 India Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 88 India Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 89 India Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 90 Japan Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 91 Japan Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 92 Japan Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 93 Japan Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 94 Japan Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 95 South Korea Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 96 South Korea Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 97 South Korea Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 98 South Korea Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 99 South Korea Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 100 Australia & New Zealand Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 101 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 102 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 103 Australia & New Zealand Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 104 Australia & New Zealand Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 105 Indonesia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 106 Indonesia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 107 Indonesia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 108 Indonesia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 109 Indonesia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 110 Malaysia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 111 Malaysia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 112 Malaysia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 113 Malaysia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 114 Malaysia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 115 Singapore Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 116 Singapore Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 117 Singapore Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 118 Singapore Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 119 Singapore Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 120 Vietnam Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 121 Vietnam Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 122 Vietnam Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 123 Vietnam Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 124 Vietnam Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 125 Rest of APAC Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 126 Rest of APAC Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 127 Rest of APAC Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 128 Rest of APAC Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 129 Rest of APAC Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 130 Latin America Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 131 Latin America Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 132 Latin America Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 133 Latin America Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 134 Latin America Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 135 Latin America Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 136 Brazil Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 137 Brazil Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 138 Brazil Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 139 Brazil Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 140 Brazil Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 141 Mexico Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 142 Mexico Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 143 Mexico Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 144 Mexico Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 145 Mexico Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 146 Argentina Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 147 Argentina Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 148 Argentina Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 149 Argentina Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 150 Argentina Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 151 Peru Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 152 Peru Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 153 Peru Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 154 Peru Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 155 Peru Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 156 Rest of LATAM Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 157 Rest of LATAM Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 158 Rest of LATAM Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 159 Rest of LATAM Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 160 Rest of LATAM Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 161 Middle East & Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 162 Middle East & Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 163 Middle East & Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 164 Middle East & Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 165 Middle East & Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 166 Middle East & Africa Minimal Residual Disease Testing Market Share, By Country, By Value, 2019–2029

Table 167 Saudi Arabia Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 168 Saudi Arabia Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 169 Saudi Arabia Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 170 Saudi Arabia Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 171 Saudi Arabia Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 172 UAE Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 173 UAE Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 174 UAE Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 175 UAE Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 176 UAE Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 177 Qatar Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 178 Qatar Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 179 Qatar Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 180 Qatar Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 181 Qatar Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 182 Kuwait Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 183 Kuwait Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 184 Kuwait Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 185 Kuwait Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 186 Kuwait Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 187 South Africa Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 188 South Africa Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 189 South Africa Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 190 South Africa Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 191 South Africa Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 192 Nigeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 193 Nigeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 194 Nigeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 195 Nigeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 196 Nigeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 197 Algeria Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 198 Algeria Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 199 Algeria Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 200 Algeria Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 201 Algeria Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 202 Rest of MEA Minimal Residual Disease Testing Market Size, By Value (USD Million), 2019–2029

Table 203 Rest of MEA Minimal Residual Disease Testing Market Share, By Test Type, By Value, 2019–2029

Table 204 Rest of MEA Minimal Residual Disease Testing Market Share, By Technology, By Value, 2019–2029

Table 205 Rest of MEA Minimal Residual Disease Testing Market Share, By Application, By Value, 2019–2029

Table 206 Rest of MEA Minimal Residual Disease Testing Market Share, By End Use, By Value, 2019–2029

Table 207 Abbott Laboratories Company Overview

Table 208 Abbott Laboratories Financial Overview

Table 209 Adaptive Biotechnologies Company Overview

Table 210 Adaptive Biotechnologies Financial Overview

Table 211 Agilent Technologies Company Overview

Table 212 Agilent Technologies Financial Overview

Table 213 ARUP Laboratories Company Overview

Table 214 ARUP Laboratories Financial Overview

Table 215 Bio-Rad Laboratories Company Overview

Table 216 Bio-Rad Laboratories Financial Overview

Table 217 F. Hoffmann-La Roche AG Company Overview

Table 218 F. Hoffmann-La Roche AG Financial Overview

Table 219 Illumina, Inc. Company Overview

Table 220 Illumina, Inc. Financial Overview

Table 221 Invivoscribe, Inc. Company Overview

Table 222 Invivoscribe, Inc. Financial Overview

Table 223 Janssen Diagnostics LLC Company Overview

Table 224 Janssen Diagnostics LLC Financial Overview

Table 225 Luminex Corporation Company Overview

Table 226 Luminex Corporation Financial Overview

Table 227 Myriad Genetics, Inc. Company Overview

Table 228 Myriad Genetics, Inc. Financial Overview

Table 229 Natera, Inc. Company Overview

Table 230 Natera, Inc. Financial Overview

Table 231 QIAGEN N.V. Company Overview

Table 232 QIAGEN N.V. Financial Overview

Table 233 Sysmex Corporation Company Overview

Table 234 Sysmex Corporation Financial Overview

Table 235 Thermo Fisher Scientific, Inc. Company Overview

Table 236 Thermo Fisher Scientific, Inc. Financial Overview

Market Segmentation

No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

1. What are the major factors driving the growth of Global Minimal Residual Disease Testing Market?

Ans: Major factors driving the growth of Global Minimal Residual Disease Testing Market include growing prevalence of cancer worldwide, leading to increased demand for accurate and reliable diagnostic tests, increasing adoption of precision medicine approaches, and growing trend towards early cancer diagnosis and detection.

2. What is the current market size of Global Minimal Residual Disease Testing Market?

Ans: Global Minimal Residual Disease Testing Market size was estimated at USD 1.54 billion in 2022.

3. Which segment accounts for the highest market share in the Global Minimal Residual Disease Testing Market by application?

Ans: The hematological malignancies segment is expected to hold the highest market share in the Global Minimal Residual Disease Testing Market by application.

4. Which segment accounts for the highest market share in the Global Minimal Residual Disease Testing Market by end user?

Ans: The hospitals segment is expected to hold the highest market share in the Global Minimal Residual Disease Testing Market by end user.

5. Name the key players in Global Minimal Residual Disease Testing Market.

Ans: Key players in the Global Minimal Residual Disease Testing Market include Abbott Laboratories, Adaptive Biotechnologies, Agilent Technologies, ARUP Laboratories, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Illumina, Inc., Invivoscribe, Inc., Janssen Diagnostics LLC, Luminex Corporation, Myriad Genetics, Inc., Natera, Inc., QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.

PLACE AN ORDER

SINGLE USER LICENSE
$ 4850
GROUP LICENSE
$ 5750
ENTERPRISE LICENSE
$ 8150
EXCEL DATA PACK
$ 3250

Request for Sample

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Custom Research Service

Ask the Analyst to customize an exclusive study to serve your research needs
Quality & Accuracy

Ask the Analyst to customize an exclusive study to serve your research needs
Data Visualization

As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
Information security

We never share your personal and confidential information. Your personal information is safe and secure with us.

Minimal Residual Disease Testing Market

Report Overview

Market Segmentation

To request a free sample copy of this report, please complete the form below.

Frequently Asked Questions (FAQs):

1. What are the major factors driving the growth of Global Minimal Residual Disease Testing Market?

2. What is the current market size of Global Minimal Residual Disease Testing Market?

3. Which segment accounts for the highest market share in the Global Minimal Residual Disease Testing Market by application?

4. Which segment accounts for the highest market share in the Global Minimal Residual Disease Testing Market by end user?

5. Name the key players in Global Minimal Residual Disease Testing Market.

PLACE AN ORDER

RELATED REPORTS

WHY CHOOSE US

24/7 Research Support

Custom Research Service

Quality & Accuracy

Data Visualization

Information security